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A B S T R A C T
The acute or chronic drug treatments for different neurodegenerative and psychiatric disorders are challenging
from several aspects. The low bioavailability and limited brain exposure of oral drugs, the rapid metabolism,
elimination, the unwanted side effects and also the high dose to be added mean both inconvenience for the
patients and high costs for the patients, their family and the society. The reason of low brain penetration of the
compounds is that they have to overcome the blood-brain barrier which protects the brain against xenobiotics.
Intranasal drug administration is one of the promising options to bypass blood-brain barrier, to reduce the
systemic adverse effects of the drugs and to lower the doses to be administered. Furthermore, the drugs ad-
ministered using nasal route have usually higher bioavailability, less side effects and result in higher brain
exposure at similar dosage than the oral drugs. In this review the focus is on giving an overview on the ana-
tomical and cellular structure of nasal cavity and absorption surface. It presents some possibilities to enhance the
drug penetration through the nasal barrier and summarizes some in vitro, ex vivo and in vivo technologies to test
the drug delivery across the nasal epithelium into the brain. Finally, the authors give a critical evaluation of the
nasal route of administration showing its main advantages and limitations of this delivery route for CNS drug
targeting.
1. Introduction
Since the eighties, intranasal drug administration has gained
growing interest. The nasal pathway represents a non-invasive admin-
istration route of active pharmaceutical ingredients for local, systemic
and CNS action. Although, the nasal epithelium appears as a tight
barrier, the tightness of the intercellular junctional complex of the nasal
mucosa is low due to leaky epithelial tissue (Deli, 2009; Wolburg et al.,
2008). In addition, the extensive vascularization of the mucosa, lamina
propria and the leaky epithelium provide an optimal absorption surface
for the drug delivery (Lungare et al., 2016; Wengst and Reichl, 2010).
The direct absorption of the molecules through the trigeminal and ol-
factory pathways from the nasal cavity provides a direct entrance to the
brain and results in beneficial pharmacokinetic/pharmacodynamics
(PK/PD) profile for CNS acting drugs. Furthermore, this route of ad-
ministration is a new, promising alternative pathway to enteral and
systemic drug administration for dosing highly potent and efficacious
CNS targeted drugs to reach the brain parenchyma by bypassing the
main physiological barriers: blood-brain barrier (BBB) and blood-cere-
brospinal fluid barrier (B-CSF-B). The brain capillary endothelial cells
surrounding with pericytes and astrocyte endfeet and also by the basal
lamina forms the BBB which limits the brain entrance of xenobiotics. B-
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CSF-B includes the interface of brain and cerebrospinal fluid at the
surface of cerebral ventricles and this barrier limits the transport be-
tween the liquor (CSF) and the brain parenchyma. At the nasal cavity
the molecular diffusion bypass these barriers and the drugs are oriented
directly toward the brain.
Active pharmaceutical ingredients absorbed in the nasal mucosa can
not only have local and/or systemic effect, but they can also be used to
target the brain directly (Gartziandia et al., 2016; Singh et al., 2016).
The nasal route of drug administration has several advantages over oral
or intravenous administration, which include non-invasiveness, self-
administration, shorter time to onset of effect and higher bioavailability
due to avoidance of hepatic first-pass metabolism. Moreover, bypassing
the BBB may potentially increase central nervous system (CNS) avail-
ability of the drug (Dufes et al., 2003).
This article gives an overview of the nose-to-brain route, focusing on
the anatomy of nasal cavity and the cellular and molecular mechanisms
playing an important role in the nasal drug administration and drug
penetration to the brain. After this introductory part various in vitro, ex
vivo and in vivo models for investigation of intranasal drug delivery will
be presented based on the latest literature of the field. Then some
studies which evaluate the intranasal penetration of drugs for different
CNS indications will be shown. Finally the methods to improve the
nasal drug delivery will be summarized and a critical evaluation of the
nasal drug administration route will be given based on the limitations
and the advantages of this technique.
2. Anatomy and cellular structure of the human nasal cavity
To study nasal drug absorption and the pathways molecules need to
penetrate before reaching the brain, it is crucial to get to know its
function and the anatomical and cellular structure of the nasal cavity.
The nose is responsible for multiple physiological functions such as
olfaction and respiration. It is comprised of two symmetric cavities,
divided by the septum which lies along the midsagittal plane (Crowe
et al., 2018) (Fig. 1A). The nasal cavity and the oral cavity are separated
from each other by the palatine bone. The cavities are lined with a layer
of mucosa, and the total area of both nasal cavities is ∼150–160 cm2
(Lochhead and Thorne, 2012; Mygind and Änggård, 1984; Mygind and
Dahl, 1998).
These cavities can be further divided into three regions (Fig. 1B).
The first is the vestibular region, which is the most anterior and is lo-
cated immediately at the nostril openings. Its surface area is around
0.6 cm2 and contains nasal hairs which serve to filter inhaled particles.
The primary cell type in this area are squamous epithelial cells, with
few if any ciliated cells. Due to the small surface area and the cellular
structure, the absorption of drugs is very limited in this region. The
respiratory region covers the lateral walls of the nasal cavities, in-
cluding the three projecting turbinates (lower, middle and upper nasal
turbinates). This region has the largest area at ∼130 cm2, and it is also
the most vascular region (Watelet and Van Cauwenberge, 1998). There
are four principal cell types: goblet, ciliated, non-ciliated columnar and
basal cells. Goblet cells secrete mucin to create the mucus layer together
with some of the nasal glands, which is turned over at varying rates
(Merkus et al., 1998) depending on the environment such as humidity
and temperature, but also depending on various circadian factors. Basal
cells are the key cells in the nasal cavity being able to develop into all
the other types, when needed.
The mucus is able to trap numerous molecules and deliver them to
the throat where after they are swallowed into the GI tract. Therefore,
drugs must pass through this mucus layer to reach the surface of the
epithelium and be absorbed. Higher viscosity of the mucus causes lower
clearance rate, but may also ideally allow larger percentages of doses of
drugs to penetrate the mucus and reach their intended target. Basal
cells are located on the basolateral aspect of the epithelium in contact
with the basement membrane. They are able to grow and mature into
the cells needed in every region of the nasal cavity. The ciliated and
columnar cells possess numerous microvilli (and cilia) which ad-
ditionally increases the surface area. This large surface area combined
with the high degree of vascularity makes the respiratory region a great
site for drug absorption to the systemic circulation rather than to the
CNS (Arora et al., 2002). This respiratory region is innervated by the
maxillary and ophthalmic branches of the trigeminal nerve (V1, V2),
which originates in the pons of the brainstem, and presents a possible
target nerve for transporting drugs to the CNS in addition to the ol-
factory pathway (Figs. 2–4) (Crowe et al., 2018).
The nasal septum also contains a small opening or a small depres-
sion close to the base of the nasal septum where the vomeronasal-ter-
minalis nerve is accessible via the vomeronasal organ (VNO)
(Gizurarson, 2012). The VNO is known to be essential in newborns
(Leon, 1998), but it is still debated if it is available in adults. If avail-
able, active drugs may be absorbed through the VNO and via the ter-
minalis nerve directly into the brain (Monti-Bloch et al., 1998) (Fig. 5).
The transportation of molecules from the nasal cavity to the par-
enchyma of the brain occurs along both the olfactory or trigeminal
nerves (Figs. 2–4). Once the molecules are delivered to the origins of
the nerves in the cerebrum and pons, respectively, they are able to
disperse throughout the brain following certain pathways. This trans-
portation process occurs via two pathways – intracellular and
Fig. 1. The anatomy of the human nasal cavity. (A) Histological section of human nasal cavity (Nasal Cavity, 2017, http://www.therespiratorysystem.com/nasal-
cavity/), (B) schematic view of the internal structure of human nasal cavity.
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extracellular (Fig. 3). The intracellular mechanism starts with inter-
nalization of the molecule by an olfactory neuron, trafficking of the
endocytic vesicle within the cell to the neuron's projection site, and
finally release via exocytosis (Fig. 3). The extracellular pathway starts
with the drug crossing the nasal epithelium to the lamina propria where
the neurons are located and especially in the olfactory region of the
nasal cavity, before being transported externally along the length of the
neuronal axon by bulk flow processes. The axon leads into the CNS,
where the drug is distributed further via fluid movement. The pene-
tration of drugs through endothelial cells in the lamina propria or from
the subarachnoid CSF into the brain parenchyma suppose the ability of
the molecules to cross BBB and blood-CSF barrier (Crowe et al., 2018).
2.1. Olfactory and trigeminal pathways
Intracellular and paracellular pathways of drug transport from nasal
cavity to the CNS through olfactory neurons and supporting cells are
shown in Fig. 3.
The trigeminal nerve conveys sensory information from the nasal
cavity, the oral cavity, the eyelids, and the cornea, to the CNS via the
ophthalmic division (V1), the maxillary division (V2), or the man-
dibular division (V3) of the nerve (Clerico et al., 2003; Gray, 1978).
Branches from the ophthalmic division of the trigeminal nerve provide
innervation to the dorsal nasal mucosa and the anterior portion of the
nose, while branches of the maxillary division provide innervation to
the lateral walls of the nasal mucosa. The mandibular division of the
trigeminal nerve extends to the lower jaw and teeth, with no direct
neural inputs to the nasal cavity. The three branches of the trigeminal
nerve come together at the trigeminal ganglion and extend centrally to
enter the brain at the level of the pons, terminating in the spinal tri-
geminal nuclei in the brainstem (Dhuria et al., 2010) (Fig. 4).
3. Models for testing direct nose-to-brain delivery
Drug delivery into CNS via nasal pathway has been reported in
humans and animal models of AD (Jogani et al., 2008), brain tumors
(Hashizume et al., 2008), epilepsy (Barakat et al., 2006), pain (Westin
et al., 2005) etc. The nose-to-brain route via olfactory and respiratory
epithelium may involve paracellular, transcellular and neuronal trans-
port (Illum, 2003, 2000).
Models of nasal drug delivery can be used for detecting and testing
nasal drug absorption and permeation, for PK/PD studies, toxicological
and electrophysiological studies, and also for assessment of drug
transporter interaction and the nasal barrier.
Models commonly used in nasal drug delivery experiments are in
vitro, in vivo and ex vivo models. The different models can be used for
various studies. in vitro techniques permit permeation and diffusion
studies, while in vivo models are suitable for characterization of nasal
absorption and also for pharmacokinetic profile determination of a drug
and finally, ex vivo technique can be performed to study the nasal
perfusion (Chhajed et al., 2011). All these models are discussed below.
3.1. In vivo models models
For efficiently studying the nasal delivery systems, adequate in vivo
models are essential. It is important to study the anatomy of the nasal
cavity of the animal before selecting appropriate animal model for an in
vivo nasal absorption studies. The rat model was the first animal model,
presented in the late 1970s, and afterwards, with the development of
the nasal absorption studies the mouse, rabbit, dog, sheep and monkey
were used as well. Representative reports on different species/strains of
experimental animals used for intranasal drug administration studies
are presented in Table 1.
Mouse and rat models are very useful for preliminary studies of
nose-to-brain drug absorption, while rabbit, dog and sheep models are
more frequently used for pharmacokinetic studies.
Fig. 2. Intranasal drug transport through the olfactory route to the CNS by
intracellular and extracellular pathways. Drug is taken up by OSNs which
project to the olfactory bulb. The extracellular route is between the SCs, where
the drug passing through the tight junctions (TJs), paracellular cleft, the lamina
propria, perineural space, and ultimately to the subarachnoid space where it is
transported to distal targets around the CNS. Abbreviations: Support cells (SC),
olfactory sensory neurons (OSN), olfactory ensheathing cells (OEC), olfactory
nerve fibroblasts (ONF). After Crowe et al. (2018).
Fig. 3. The initial processes at intracellular and extracellular mechanisms of
intranasal drug transport to the CNS. Intracellular shows pinocytosis/en-
docytosis (1), trafficking of endosome to Golgi apparatus (2), sorting with the
Golgi stacks (3), and axonal transport toward olfactory bulb (4). Extracellular
pathway shows movement of drug to the paracellular space and translocations
through an absent tight junction (TJ) (6), and finally translocation to the lamina
propria through the paracellular cleft (7). Abbreviations: olfactory sensory
neuron (OSN), supporting cells (SC), endosome (EN), Golgi apparatus (GA),
exosome (E) and tight junction (TJ).
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However, results of studies obtained from animal models do not
always correlate well with those of humans, because of the anatomical
and physiological differences of their nasal cavities (Cho et al., 2010).
The direct transfer of drugs from the olfactory mucosa to the CNS is
usually divided into transfer within the nerve axon, or outside the
nerve. Both pathways provide potential for bypassing the blood-brain
barrier (BBB).
The solubility and the potency of the drug is usually the limiting
factor, since the absorption capacity is limited. It is important to note
that direct nose-to-brain absorption avoids preabsorption metabolism,
first pass effect, as well as dilution caused by distribution and protein
binding. The dosage to be delivered to the olfactory region or to be
absorbed neuronally may easily be as low as 0.01–1% of oral dosage. It
is also important that the drug is soluble in those few microliters that
will be administered intranasally. The clearance inside the nasal cavity
is so rapid that if the drug need to be dissolved before being absorbed,
the time is usually not enough for the dissolution process, before being
absorbed.
The nasal formulation of drugs is usually administered with a
Fig. 4. Trigeminal innervation of the nasal respiratory region in rodents. The respiratory mucosa includes the respiratory epithelium and its underlying lamina
propria (panel A). Fibers of the trigeminal nerve, important for conveying chemosensory, nociceptive, touch, and temperature inputs, are found throughout the nasal
epithelium where their free nerve endings extend nearly to the epithelial surface, just below tight junctions (TJ). Central projections of the trigeminal nerve are
shown in panel B. The cell bodies of the trigeminal nerve fibers are located in the semilunar ganglion; their axons project into the brainstem at the level of the pons.
Of the three main trigeminal nerve divisions (V1, the ophthalmic nerve; V2, the maxillary nerve; and V3, the mandibular nerve), only V1 and V2 send branches to the
nasal epithelium. Modified from Lochhead and Thorne (2012).
Fig. 5. The key extracellular routes of molecules from the nasal penetration
surface to the CNS following intranasal administration. Modified from Crowe,
Life Sciences, 2018 (Crowe et al., 2018).
Compounds that may be absorbed by the trigeminal nerve are transported to
the ganglion, where after they enter the brain.
Table 1
Commonly used animals in intranasal drug administration studies.
Animal Strain Tools for administration Volume administered per nostril
(μl)
Subject of the study References
dogs Labrador
Retriever
mucosal atomizer device 2400 analgesic treatment Micieli et al. (2017)
guinea pigs Hartley pipette/syringe 10 induction of rhinitis Mizutani et al. (2003)
mice CD-1 micropipette 10 insulin delivery to the brain Salameh et al. (2015)
Balb/c micropipette 5 morphin administration Westin et al. (2005)
monkeys Rhesus monkey modified nasal atomizer 50–200 opioid administration Saccone et al. (2016)
rabbits New Zealand spray 200 insulin absorption Najafabadi et al. (2004)
Japanese White nasal actuator 100 new-generation corticosteroid treatment Sato et al. (2007)
rats Wistar intranasal cannula 40 minimal-stress model for intranasal administration in
freely moving rats
Stevens et al. (2009)
Sprague-Dawley pipette/syringe 50 morphin administration Westin et al. (2005)
sheeps Karaman cannula 2000 admnistration of different nasal formulations Karasulu et al. (2008)
Suffolk syringe 1000 intranasal inoculation with prion to compare different
scrapie strains
Moore et al. (2016)
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pipette or using a polyethylene tube attached to a micropipette, in-
serted approximately 3mm (in mice) or 5mm (in rats) into the nostril.
In the study of Westin et al. the received volume of the intranasal ad-
ministration is 5 μl for mice and 50 μl for rats and the drug was ad-
ministered into the right nostril (right-sided administration), so the left
olfactory bulb could serve as a control (Westin et al., 2005). It is im-
portant to keep the animals in a supine position in order to increase the
chance for the drug to reach the olfactory region or the upper part of
the nasal cavity where is direct access to the brain. In humans, the
olfactory region covers about 10% of the nasal cavity with limited ac-
cess. In mice and rats, however, the olfactory region covers about 50%
of the nasal cavity. The olfactory region of monkeys is similar to that of
humans and lies in the upper part of the nasal cavity. Nasal anatomy of
rabbits and dogs are similar, where there are branched complex con-
chae inside the nasal cavity, although the surface area of dogs is larger
and the olfactory region is located primarily on the ethmoidal conchae
(Gizurarson, 1990). Anatomical factors affecting nasal absorption are
summarized in Table 2.
3.2. In vitro models
Whereas in vivo studies are most substantial for any nasal drug ab-
sorption and permeation tests, mechanistic aspects of nasal absorption
and the drug transport can be more clearly studied and controlled by in
vitro studies. Mainly two cell lines (RPMI 2650 and CaCo-2) are used to
assess nasal absorption and permeability. It should be noted that these
cellular models provide information on the transport across the cells or
paracellular, but concurrent factors such as mucus, mucins, clearance,
anatomical and physiological factors involved in keeping the nose
functional may also affect the absorption. Additionally, the cellular
models contain receiving lumen that does not fully reflect the required
transport from the mucosa to the receiving nerves.
3.2.1. RPMI 2650 a cell culture model of the nasal barrier
RPMI 2650 is derived from the human nasal epithelial tissue, a
human nasal squamous cell carcinoma (a spontaneously formed tumor)
of the nasal septum. A cell culture model based on human RPMI 2650
cell line does not form monolayers, only grows to multilayer, thus it is
commonly used for nasal metabolism studies and also for toxicity assays
(Kürti et al., 2013; Wengst and Reichl, 2010). Although RPMI 2650 cell
line is not suitable for drug transport study, its application for drug
permeation studies has been reported (Bai et al., 2008). The serially
passaged RPMI 2650 cells form confluent cell monolayer under con-
trolled conditions. These conditions include cultivating medium for
cells and the additives for the cellular differentiations. Each monolayer
creates tight junctions with a transepithelial electrical resistance
(TEER) value enabling transportation of drugs.
Werner and coworker studied the transportation of drugs in vitro
using transwell insert, which is a permeable support device that provide
independent access to both sides of a monolayer (Schmidt et al., 1998;
Werner and Kissel, 1995). Although the contamination of epithelial
cells with pathogens can be a problem, this method is convenient for
evaluating the transport and metabolism of peptides (Hoang et al.,
2002).
There are two types of culture conditions of these passaged mono-
layers, the air-liquid interface (ALI) and the liquid-covered culture
(LCC) (Dolberg and Reichl, 2016). In LCC model both apical and ba-
solateral sides are filled with cell culture medium. Morphologically is
characterized with denuded and flattened ciliated cells with relatively
weak mucin expression and TEER value peak on the second day and
then decrease rapidly. In ALI model both apical and basolateral sides
are filled with cell culture medium, and then apical side is exposed to
the air, after which the medium in basolateral side is changed every
second days. Morphological appearance is much close to the nasal
tissue in vivo with number of ciliated cells and stronger mucin gene
expression. Maximum TEER value is appeared on day 5, and high TEER
value is maintained over 10 days. These differences between LCC and
ALI models show that ALI condition compared to LCC could provide
more adequate environment for drug transport studies.
RPMI 2650 cells in ALI culture could be used as first screening tool
for cytotoxicity and permeability in the preclinical evaluation and
comparison of solid formulations for intranasal delivery of drugs
(Gonçalves et al., 2016).
3.2.2. CaCo-2 cell line
Another common cell culture model is CaCo-2 cell line that has been
used for three decades and is suitable to evaluate the nasal absorption
of the formulations. The cell line is derived from human colon carci-
noma and differentiates to various monolayers slowly. Caco-2 cell
culture is the most suitable model to assess the drug absorption and
permeability trough the intestinal epithelia (Dolberg and Reichl, 2016;
Dyer et al., 2002; Qian et al., 2018; Tan et al., 2018)
Reconstructed human nasal mucosa (the three-dimensional re-
constructed human nasal mucosa model of permeation barriers)
Reconstructed three-dimensional model uses isolated human nasal
fibroblasts in collagen matrix covered by RPMI 2650 epithelial cells. A
collagen matrix containing fibroblasts is used as a growth support for
the epithelial cells. The three-dimensional reconstructed nasal mucosa
model shows comparable permeation barrier properties and four –to
five- times faster paracellular permeation than in the epithelial cell
model. Although the disadvantage of this three-dimensional model is
the more complex handling of the constructs it is promising model to
evaluate passive permeation of substances trough the nasal mucosa
(Wengst and Reichl, 2010).
3.3. Ex vivo models
In the development of medications for nasal administration, reliable
study models are essential. Determination of toxic effects of excipients
and transmucosal transport of drugs are usually performed ex vivo using
nasal mucosa from experimental or slaughtered animals. Frequently
utilized ex vivo excised animal tissue models are obtained from rats,
rabbits, dogs, sheep, monkeys, but from humans as well.
Studies with excised tissues are useful to obtain information on
Table 2
Characteristics of nasal cavity of different species (modified from Gizurarson, 1990).











dog 20 10 210 branched conchae no Craven et al. (2007)
guinea pig 0.9 3.4 27 double scroll yes Schreider (1983)
mouse 0.03 0.5 2.8 double scroll yes Gross et al. (1982)
monkey 8 5.3 62 single scroll no Schreider (1983)
rabbit 6 5.2 61 branched conchae no Gizurarson (1990)













Gizurarson (1990) and Proctor and
Anderson (1982)
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permeation, metabolism, efflux, and toxicity. Despite of the numerous
advantages of the ex vivo models for nasal delivery of drugs they have
also some limitations. The most important limitation factor is the
thickness of nasal epithelial tissues of animal species and the lack of
interstitial flow rate underneath the mucosa. To obtain information on
permeability it becomes difficult to extrapolate the results to in vivo
models (Cho et al., 2010).
For nasal drug delivery, it is essential to investigate some factors
that may affect the extent and the rate of drug absorption. These factors
are metabolic stability, permeation mechanisms, and formulation of the
drug.
The well-known ex vivo nasal perfusion model for drug permeability
is the Ussing chamber. The use of this model is simple so it is very easy
to monitor and maintain viability of tissues throughout the study. On
the basis of permeability study, it is possible to quantify passive diffu-
sion, active transport, efflux transport as well as identify and char-
acterize (compound)-specific carrier-mediated routes of transport (Li
et al., 2004). The efflux pumps, identified in the nasal mucosa, are
important to study in these models with and without compounds that
may block these pumps (Hosoya et al., 1994). In addition, the Ussing
chamber model offers to compare the transport of drugs of the nasal
respiratory and olfactory mucosa (Espefält Westin, 2007).
In sum, ex vivo models are very popular as drug screening models,
especially for drug delivery studies, during the early phase of drug
development.
4. Intranasal application of different drugs for CNS indications
Several CNS drugs barely pass through the BBB and even if they can
penetrate into the brain efficiently, they cause adverse effects in the
periphery (Hanson and Frey, 2008). These are the main reasons why it
was important to find an alternative route of administration to deliver
CNS drugs directly into the brain. Besides evading the BBB and mini-
mizing peripheral exposure (Born et al., 2002), first-pass metabolism,
slow absorption, fast elimination and plasma protein binding (Lindup
and Orme, 1981) are additional factors to be considered at adminis-
tration of CNS acting drugs. Intranasal (IN) administration an alter-
native option contrary to enteral or intravenous administration. Schiöth
et al. (2012) reported that Insulin-like growth factor 1 (IGF-1) had
significantly higher CNS exposure when it was administered in-
tranasally compared to IV dosing (Schiöth et al., 2012)
Many CNS-associated diseases have already been treated with IN
administration of drugs, like obesity, eating disorders, AD (AD),
Parkinson's Disease (PD), Huntington Disease (HD), depression, an-
xiety, autism, seizure, addiction and stroke and numerous new pro-
mising drugs are under development for IN application (Chapman et al.,
2013).
4.1. Preclinical data
Many intranasal medications are still in preclinical phase of devel-
opment. Some of these studies are targeting memory and learning, that
show potential treatment for neurodegenerative disorders like AD, PD,
epilepsy and other neurotoxic events like oxidative stress and ischemia
and other diseases as it can be seen in Table 3.
4.1.1. Learning and memory, neurodegenerative diseases
[Ser(2)]exendin(1–9) is an agonist of glucagon-like peptide-1 (GLP-
1) receptor (due to its homology to a conserved domain in the glu-
cagon/GLP-1 family) that used to facilitate learning and has been
shown to decreases that IN [Ser(2)]exendin the occurence of kainic
acid-induced apoptosis in mouse models after IN administration
(During et al., 2003). The radioactive compound can be detected in the
lymph nodes and blood and also in the olfactory bulb, that means an
efficient uptake through nose-to-brain besides the nose-to-blood-to-
brain path.
IN administration of NAP, an eight amino acid peptide (the se-
quence is NAPVSIPQ) derived from activity-dependent neuroprotective
protein (ADNP) has improved memory function in normal and cogni-
tively impaired rats and decreased anxiety in aged mice (Alcalay et al.,
2004; Gozes et al., 2000). Gozes et al. had shown with reversed phase-
HPLC that (3)H-labeled NAP reaches the brain unchanged after 30min
from administration and by the 60-minute mark it reaches its maximum
concentration in the brain cortex (Gozes et al., 2000). In AD models and
chronic administration improved spatial learning and memory, in-
creased soluble tau, and decreased neurofibrillary tangles in tauopathy
(Shiryaev et al., 2009). In a mouse model of schizophrenia, IN NAP
decreased hyperactivity and protected visual memory (Gozes, 2011).
Another study also showed that IN NAP reduces oxidative stress in rats
subjected to chronic hypoxia (Sharma et al., 2011). However the exact
route of NAP was not detailed in these publication only that NAP has
reached sufficient amount of concentration in the brain to have its ef-
fect.
The neuropeptide pituitary adenylate cyclase-activating polypeptide
(PACAP) has shown neuroprotective and neurotrophic properties,
beneficial in an AD model, following chronic IN administration (Rat
et al., 2011). The radioactive peptide ([125I]PACAP27 was used) has
been showed to reach the CNS after 5min and the maximal con-
centration (about 0,1% of initial radioactivity) was detected 15min
after administration. However the exact route of the drug (nose-to-brain
or nose-to blood-to-brain) was not investigated. For comparison, in
another study about 0.11% of the total intravenous dose of PACAP
crossed the BBB (Banks et al., 2002).
Recombinant human nerve growth factor (NGF) has been shown to
reach the olfactory bulb and most part of the brain in significantly
higher concentrations after 30–45min following IN administration as
compared to a matched IV dose (Chen et al., 1998). IN nerve growth
factor (NGF) in a NGF-deficient transgenic mouse model of AD showed
successful rescue of recognition memory deficits (Capsoni et al., 2002;
De Rosa et al., 2005) and a behavioral analysis also showed that it has
antidepressant like effects in animals by reduction of the immobility
time in forced swimming test (FST) and tail suspension test (TST)
(Capsoni et al., 2002). IN NGF also decreased epileptic seizure onset
probability and duration in rats (Lei et al., 2017).
IN administration of L-3,4-Dihydroxyphenylalanine (L-DOPA) show
that L-DOPA is easily absorbed into the systemic circulation and from
there into the CNS. In a study carried out by Chao et al. they pre-treat
the animals causing certain lesions to the brain, and following recovery
they administer L-DOPA intranasally and carry out tests using bensar-
azide showing that L-DOPA is able to reach the brain directly, bypassing
the blood-brain barrier (Chao et al., 2012).
IN IGF-I was found to be a suppressor of ataxin-1-mediated adverse
effects (Vig et al., 2006), the protein that causes spinocerebellar ataxia
type 1 (SCA1) (Burright et al., 1995), therefore, this administration may
be a therapeutic alternative for this disease. The severity of SCA1 was
examined with accelerating rota rod test: the group was treated with
saline and as the animals get used to the task they improved their
performance while the SCA1 saline treated mice failed to improve.
However the IGF1 (60 g) treated animals were almost similar to SCA1
saline treated group, on the third day of the study the animals per-
formed better (p < 0.05) than SCA1 saline treated animals (Vig et al.,
2006).
There are CNS drugs that not only inhibit the neurodegenerative
processes but are also able to prevent it or help in the regeneration. IN
Calcitonin gene-related peptide has been shown to improve cerebral
blood flow, reduce cortical and endothelial cell death, increase the le-
vels of vascular endothelial growth factor (VEGF) and stimulate an-
giogenesis and resulted in significantly higher levels in the CSF, cortex,
and hippocampus relative to IV administration (Sun et al., 2010).
The IN combination of Erythropoietin (EPO) and IGF-1 significantly
reduced infarct volumes in case of middle cerebral artery occlusion
(MCAO) and improved neurological function up to 90 days later. A
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study has showed that the PI3K/Akt signaling pathway mediates the
synergistic effect of EPO+ IGF-I and by inhibiting phosphorylation of
Akt, the cytokines lose their neuroprotective effect in the cere-
brocortical neurons. (Digicaylioglu et al., 2004) EPO+ IGF-I increased
both Akt phosphorylation and GSK-3 phosphorylation and inhibiting
tau hyperphosphorylation (Kang et al., 2010). This study also had
confirmed the involvement of the PI3K/Akt/GSK-3 pathway by using a
PI3K inhibitor. EPO+ IGF-I also prevented HIV/gp120-induced neu-
ronal cell death in cultures and in vivo transgenic mouse models of
human immunodeficiency virus (HIV) infection (Kang et al., 2010). IN
NGF also has enhanced neurogenesis in the striatum and improved
functional recovery when administered after a day following MCAO
(Zhu et al., 2011) and decreased the neuron loss in the epileptic brain
(Lei et al., 2017).
Direct transport of VEGF to the CNS has also been shown after in-
tranasal administration (Yang et al., 2009). Intranasal delivery of re-
combinant human VEGF also reduced infarct volume, improved beha-
vioral recovery, and enhanced angiogenesis following MCAO (Xu et al.,
2009).
The brain distribution of recombinant human transforming growth
factor β1 (TGF-β1) was studied in rats and it was found that IN ad-
ministrated TGF-β1 was successfully delivered to many parts of the CNS
within 30min following IN administration, while there was no in-
creased level of TGF-β1 in the plasma or peripheral organs, suggesting a
direct nose-to-brain uptake (Ma et al., 2008a). IN delivery of TGF-β1
also reduced infarct volume, improved functional recovery, and in-
creased neurogenesis following MCAO (Ma et al., 2008a).
Levels of recombinant human basic fibroblast growth factor (FGF)
were significantly increased in the olfactory bulb and the striatum of
rats following IN administration (Ma et al., 2008b). When basic FGF
was delivered intranasally following cerebral ischemia/reperfusion,
improved neurological function and reduced infarct volume were ob-
served (Ma et al., 2008b). Rats which received IN basic fibroblast
growth factor daily for 6 days starting one day after MCAO also showed
enhanced neurogenesis (Wang et al., 2008).
4.1.2. Eating regulation, obesity
Preclinical studies have found promising treatment also for eating
disorders. Galanin-like peptide (GALP) is a neuropeptide that has turn
out to be a promising treatment for obesity by IN administration as it
has been successfully delivered through the olfactory bulb, into the
anterior brain, hippocampus, hypothalamus, cerebellum, brain stem,
and CSF in mice (Krasnow et al., 2003; Nonaka et al., 2008).
Although the BBB has the ability to transport leptin into the CNS
from the blood, this transport is impaired during obesity (Banks et al.,
1999), making intranasal delivery of leptin into the CNS a potential
strategy to regulate feeding behavior. A pharmacokinetic study of IN
administered radioactive leptin showed that more than 80% was de-
livered in unchanged state into the brain within 30min, with highest
levels to the hypothalamus (Fliedner et al., 2006) while after in-
travenous 125I-leptin was detected in a little less than 20% brain/serum
ratio (Hsuchou et al., 2013). IN administration of leptin has also been
shown to delay the onset of pentylenetetrazole-induced generalized
convulsive seizures in mice (Xu et al., 2008).
4.1.3. Auto-inflammatory diseases
The anti-inflammatory cytokine interferon-beta-1b (IFN-β1b) was
investigated as an intranasally administrated, non-invasive treatment
for multiple sclerosis (Ross et al., 2004). At similar blood levels, in-
travenous IFN-β1b had lower brain concentration compared to IN ad-
ministration (Ross et al., 2004).
Autoimmune responses to low-density lipoproteins (LDL) are some
of the causes of atherosclerosis. Studies have showed that immunization
with LDL can induce proatherogenic responses, like they did with in-
tranasal administration of apolipoprotein B-100 (apoB100) fused to the
B subunit of cholera toxin (Klingenberg et al., 2010). The treatment
induced a protective mucosal immune response in mice model by at-
tenuating atherosclerosis and inducing regulatory Tr1 cells that inhibit
T effector responses to apoB-100.
Another study reported the use of experimental autoimmune
myasthenia gravis (EAMG) model and intranasal drug administration to
find a treatment for myasthenia gravis, an autoimmune disease char-
acterized by muscle weakness and fatigability (Consonni et al., 2017).
Consonni et al. had designed a fusion protein, mCTA1–T146, which was
able to reinstating tolerance against acetylcholine receptors after sev-
eral days of intranasal administration.
4.1.4. Antibodies
Antibodies show limited penetration into the brain when delivered
peripherally (Banks, 2004). One of the diagnosis of meningitis is the
presence of antibodies in the CSF. The IN treatment of 22C4 single-
chain variable fragment (scFv) antibodies resulted in a reduction of
cerebral amyloid angiopathy and plaque pathology. Additionally, the
single chain Fv antibody was detected to bind to amyloid plaques in the
brains of these mice. IN delivery of full-length antibodies against glu-
tamate has resulted in anti-amnesic effects in rats subjected to prior
injection with an amyloid beta (Aβ) fragment (Aβ25–35) into the nu-
cleus basalis of Meynert. IN administration of the same antibody also
improved retention of the conditioned passive avoidance response in
rats with ischemic injury of the prefrontal cortex, although neither
study examined antibody pharmacokinetics within the brain (Gorbatov
et al., 2010; Romanova et al., 2010)
4.1.5. Gene vectors tumors and stem cell therapies
IN administration of gene vectors could be a solution to avoid the
blockade of BBB and deliver therapeutic transgenes to brain (Lochhead
and Thorne, 2012). For example, growth compromised herpes simplex
virus type 2 mutant ΔRR encoding the anti-apoptotic gene ICP10PK has
also been successfully delivered to the brain through the IN route to
prevented kainic acid-induced seizures, neuronal loss, and inflamma-
tion in both mice and rats (Laing et al., 2006).
Another successful preclinical study was the investigation of a fi-
lamentous bacteriophage, delivered a myelin oligodendrocyte protein
epitope (MOG) intranasally as a treatment of murine experimental
autoimmune encephalomyelitis (Rakover et al., 2010). Phage MOG
treatment improved neuronal function and reduced levels of proin-
flammatory cytokines such as monocyte chemoattractant protein 1
(MCP1), interferon γ (IF γ), and interleukin-6 (IL-6).
There was also a study to find out, if a brain tumor can be targeted
down with telomerase inhibitor GRN163 (Hashizume et al., 2008). The
results showed that the drug was delivered successfully to the tumor
cells without accumulating either in healthy brain cells or in the body.
Stem cells are potential treatment options for many diseases due to
their ability to replace dead cells or deliver trophic factors to damaged
areas. IN mesenchymal stem cells (MSC) have been used to treat is-
chemic brain damage in neonatal mice (Van Velthoven et al., 2010).
MSCs stimulate endogenous cerebral repair by up-regulating the repair
promoting factors in the ischemic brain (Van Velthoven et al., 2010).
Intranasal MSC treatment was also promising in treatment of sub-
arachnoid hemorrhage in a rat model (Nijboer et al., 2018).
4.2. Clinical data
Some drugs, like benzodiazepine derivatives have already been in-
vestigated in humans (Table 3). Benzodiazepines are used to terminate
seizures and to decrease the neuronal damage that a seizure can cause
in the brain. For a successful prevention, the intervention has to be fast
and it is also important that the drug should be administrated as soon as
possible already in home settings. IN benzodiazepines fulfill these ex-
pectations (Gizurarson et al., 1999; Kälviäinen, 2015). Studies have
compared different formulations of diazepam like IN midazolam, versus
IV midazolam (Bistritzer et al., 2000; Mahmoudian and Mohammad,
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2004; Mittal et al., 2006; Thakker and Shanbag, 2013), and rectal versus
IN (Bhattacharyya et al., 2006; De Haan et al., 2010; Fişgin et al., 2002;
Holsti et al., 2010). In both cases IN administration was faster and more
comfortable while in the potency there was no significant difference
between the three routes. It should be however mentioned, that the
state of the nasal mucous can interfere with IN midazolam absorption.
It can help in the absorption into the bloodstream if the blood flow is
increased but also could block the absorption from the mucosal surface
if the nasal secretion is enhanced (Bistritzer et al., 2000). When normal
nasal spray is used, the access to the olfactory region is limited, due to
the structure of the nasal cavity (Olafsson and Gizurarson, 2000). In
order to improve the access to this region, the subject need to inhale
rapidly, similar to when he wants to smell something.
Midazolam has many beneficial properties in IN formulation; it is
lipid soluble, can be absorbed fast, has rapid effect and physiological
pH and IN formulation has also better bioavailability than IV for-
mulation (Pacifici, 2014; Wermeling et al., 2006). IN diazepam also has
high bioavailability compared to rectal 89% and IV 97% formulations
(Agarwal et al., 2013; Henney et al., 2014; Ivaturi et al., 2013). Also
intranasal sprays and drops are preferred contrary to inconvenient
rectal suppositories or invasive injections (better compliance) and can
be better applied in emergency situations. Adverse effects in case of
nasal administration are nose irritation, bitter taste, and rarely cardi-
orespiratory depression (Pacifici, 2014; Streisand and Stanley, 1995).
Insulin is one of the most widely studied biologics with regard to its
effects on the CNS following intranasal administration. It is mostly
known for its role in the regulation of blood glucose level, but also has
shown beneficial effects on the CNS to decrease appetite and increase
metabolism as well as to improve memory and mood (Benedict et al.,
2004; Kern et al., 1999). IN administration of insulin and insulin sen-
sitizers have been used as treatment and as prevention on patients with
AD and mild cognition impairment (MCI) (Claxton et al., 2013; Reger
et al., 2006). In this way the adverse effects of peripheral insulin, for
example the unsafe decrease of blood glucose level can be avoided
(Born et al., 2002).
In humans, IN insulin decreased food intake, enhanced postprandial
thermogenesis, and decreased postprandial serum insulin, therefore, its
potential in helping weight loss proved seems to be evident (Benedict
et al., 2011, 2008).
Studying the differences in IN and IV administration of angiotensin
II (ANG II) in humans (Derad et al., 1998), it was found that in both
cases ANG II levels were increased. However, blood pressure was nor-
malized much faster in IN administration. IN ANG II also reduced
plasma norepinephrine and enhanced plasma vasopressin levels com-
pared to the IV administered group. In a later study Derard et al. have
also found that intranasal ANG II with ANG II type 1 receptor inhibitor
(valsartan) pretreatment can be used to treat high blood pressure
(Derad et al., 2014). There is a possibility that these differences are due
to IN ANG II binding to brain angiotensin receptors (Culman et al.,
2001). However, some studies shown that ANG II has also increase BBB
permeability through tight junctional and vesicular mechanisms
(Fleegal-Demotta et al., 2009; Guillot and Audus, 1991).
IN Melanocortin(4–10) proteins effect on human body was studied
and showed that these proteins reduce focusing of attention (Smolnik
et al., 2000) while also decrease body fat in normal weight humans
(Fehm et al., 2001). On the other hand in overweight humans the
weight regulatory system seems to be resistant to this beneficial effect
of melanocortin treatment (Hallschmid et al., 2006). Though MSH-
(4–10) barely passes through the BBB, the IN administration has shown
to be a viable route to get these peptides in an effective amount into the
brain without overdose (Fehm et al., 2000).
Oxytocin is a neuropeptide that has an important role in controlling
behavior. The BBB blocks the brain entrance of peripheral oxytocin,
therefore IN administration is a plausible solution for oxytocin to reach
the CNS (Kang and Park, 2000). IN oxytocin has been shown to increase
trust (Kirsch, 2005; Kosfeld et al., 2005) improve empathy (Domes
et al., 2007), reduce cortisol and increase anxiolytic effects in stress
(Heinrichs et al., 2003), normalize fear in generalized social anxiety
disorder (Kirsch, 2005; Labuschagne et al., 2010), and improve emo-
tional recognition in patients with autism spectrum disorders (Guastella
et al., 2010), showing that the peptide has been transported into the
brain, bypassing the blood-brain barrier.
IN orexin-A has shown to improve the performance and alter the
brain metabolic activity in sleep-deprived primate model (Deadwyler
et al., 2007) clinical data has also showed that it holds promises to
become a treatment for narcolepsy (Baier et al., 2008).
These clinical studies however, were primarily focused on the effect
of intranasal drugs, but it should be stated that most of these studies
used spray and intranasal puffs as delivery device of the drugs.
Therefore, in that case the nose-to-blood- to- brain distribution pathway
is also possible contrary to direct nose to brain transport (Table 4).
5. Penetration enhancer techniques at nasal drug delivery route
The penetration of different molecules across the nasal barrier can
be improved by various drug formulations, using different devices or by




The physicochemical properties of the drug and its potency are
crucial factors when a molecule is formulated in a solution for nasal
Table 4
Short summary of some clinical studies on intranasal drug delivery to the brain with positive outcome.
Drug name Indications References
Benzodiazepines (midazolam,
diazepam)
Epilepsy Gizurarson et al. (1999), Kälviäinen (2015), Bistritzer et al. (2000), Mahmoudian and Mohammad
(2004), Mittal et al. (2006), Thakker and Shanbag (2013), Bhattacharyya et al. (2006), De Haan
et al. (2010), Fişgin et al. (2002), Holsti et al. (2010), Pacifici (2014), Wermeling et al. (2006),
Agarwal et al. (2013), Henney et al. (2014), Ivaturi et al. (2013) and Streisand and Stanley (1995)
Insulin memory and mood enhancement, Benedict et al. (2004) and Kern et al. (1999)
Alzheimer's disease, Mild cognitive
impairment
Claxton et al. (2013) and Reger et al. (2006)
obesity (in men) Benedict et al. (2011, 2008)
Angiotensin II high blood pressure (with type 1
receptor block)
Derad et al. (2014)
increases BBB permeability Fleegal-Demotta et al. (2009) and Guillot and Audus (1991)
Melanocortin proteins weightloss (only normal weight
people)
Fehm et al. (2001) and Hallschmid et al. (2006)
Oxytocin social anxiety disorder, autism Kirsch (2005), Kosfeld et al. (2005), Domes et al. (2007), Heinrichs et al. (2003), Labuschagne et al.
(2010) and Guastella et al. (2010)
Orexin-A Narcolepsy Baier et al. (2008)
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delivery. In case of small lipophilic molecules, passive diffusion plays
an important role in the nose-to-brain delivery as reported by
Kandimalla and Donovan (2005). The size of the molecules to be de-
livered via nose to the brain is also important factor as reported by
Pardeshi and Belgamwar (2013).The absorption of dopamine (Mw
153 Da) was compared to that of the NGF (Mw 27 kDa) by Dahlin et al.
(2001). They found that brain concentrations were five-fold higher for
the small molecule dopamine than the secreted protein NGF when
dosed at the same concentration (Warnken et al., 2016). On the other
hand, the larger molecules take longer time to get transported from the
nasal cavity to the brain. Following intranasal administration, the brain
concentrations were higher in the case of small lipophilic drugs, but
they often showed larger improvement in the brain compared to other
routes of administration. Wang and coworkers studied raltitrexed, a
hydrophilic small molecule with a logP of 0.98, for brain levels fol-
lowing intranasal and intravenous administration. They showed a
54–121 fold increase in the area under the curve (AUC) in the brain
(depending on the section of the brain) after intranasal administration
compared to intravenous route in rats (Wang et al., 2006a). Wang et al.
performed similar experiments with methotrexate, which is also a hy-
drophilic drug. Here, they found that it provided greater than 13 fold
higher CSF AUC after nasal administration compared to intravenous
administration (Wang et al., 2003).
The delivery of macromolecules in solutions has also been studied
both in animal models (plasmids, IGF-I and NGF) and in humans (ar-
ginine vasopressin, insulin, oxytocin and melanocortin melanocyte-sti-
mulating hormone/adrenocorticotropin4–10 (Warnken et al., 2016).
Aqueous based solution formulations are shown to be effective drug
delivery systems for water soluble small molecules and many peptides
and proteins as it was studied both in preclinical and human studies.
5.1.2. Mucoadhesive agents
Mucoadhesive and viscosity increasing agents have been used to
increase drug residence time in the nasal cavity to allow better ab-
sorption (Touitou and Illum, 2013). By increasing the viscosity of the
formulation, with polymers such as hypromellose or polyvinyl alcohol,
it is possible to decrease mucociliary clearance (Nakamura et al., 1996;
Pennington et al., 1988). Mucoadhesive agents, such as pectin and
chitosan studied by Charlton et al, were effective at extending residence
times at the olfactory epithelium. It has also been shown that mu-
coadhesive and viscosity increasing agents increase bioavailability from
nasal formulations designed for systemic delivery (Chaturvedi et al.,
2011). To determine how the addition of a mucoadhesive agent can
influence the absorption of drugs into the brain, Khan et al. (2009)
compared brain concentrations of buspirone after intravenous admin-
istration as a solution without chitosan or cyclodextrins and in-
tranasally as a solution with 1% chitosan and 5% hydroxypropyl β-
cyclodextrin. They found that the AUC in the brain was 2.5-times
higher for buspirone in the mucoadhesive formulation than in the in-
travenous solution, and two-times as high as buspirone solution when
delivered intranasally. The cyclodextrins may have also played a role in
the increasing brain concentration by enhancing the permeability of the
drug through the tight junctions of the nasal epithelium (Khan et al.,
2009).
To test the possible toxicity of natural and synthetic mucoadhesive
ingredients in nasal formulations OECD guidelines 420 were followed
in some studies (Mangilal and Rao Patnaik, 2014; Singh et al., 2011).
5.1.3. Nanoparticles (nanosuspensions, nanoformulations)
A popular formulation method for many routes of administration is
the formation of nanosuspensions of drugs encapsulated in polymeric
carriers. These carriers may provide favorable characteristics to the
drug like enhanced absorption, mucoadhesion and increased stability.
Bhavna et al. (2014) developed a nanosuspension formulation of do-
nepezil, a cholinesterase inhibitor, for enhancing brain exposure to
treat AD. In another paper, the authors tested chitosan nanoparticles
loaded with bromocriptine (Md et al., 2014) and found that bromo-
criptine-loaded nanoparticles given intranasally produced two-fold
greater brain AUCs than that were in case of intravenous administration
of the nanoparticles. Other studies also reported nanoformulation-in-
duced enhanced drug delivery to the brain (wheat germ agglutinin (Gao
et al., 2007), olanzapine (Seju et al., 2011), lorazepam (Sharma et al.,
2014), rivastigmin (Fazil et al., 2012; Mistry et al., 2015).
Pegylation (Kamiya et al., 2018) and dendrimers are also possible
nanotechnological solutions to improve CNS drug delivery (Lu et al.,
2014) by nasal drug administration. Pegylation may increase the re-
tentivity in the nasal cavity according to Kamiya et al. (2018).
For a comprehensive review about the preparation and testing of
nanocarriers for nose to brain delivery see the recent article of Sonvico
et al. (2018). In the same article there are some marketed drugs listed
for nasal administration and CNS targeting (nicotine, Nicotrol® NS,
Pfizer, New York City, NY, USA, pain management: fentanyl, Intstanyl®,
Takeda, Japan and Pecfent/Lazanda®, Archimedes Pharma Ltd.,
Reading, UK; butorphanol tartrate spray, Mylan Inc., Canonsburg, PA,
USA, the treatment of migraine: zolmitriptan, Zomig®, AstraZeneca,
Cambridge, UK; sumatriptan, Imigran, GSK, Brentford, UK and On-
zetra™ Xsail™, Avanir Pharmaceuticals, Aliso Viejo, CA, USA).
5.1.4. Lipid based systems (microemulsions, lipid based nanoparticles)
Many groups have used lipid components like microemulsions to
increase delivery of drugs to the brain. Microemulsions can increase the
concentration of hydrophobic drugs to be delivered, as well as increase
the permeability across the membranes (Jadhav et al., 2006). Jogani
et al. (2008) developed a microemulsion formulation of tacrine for
delivery to the brain. Risperidone has also been formulated as solid
lipid nanoparticles for nose-to-brain delivery (Patel et al., 2011). Solid
lipid nanoparticles have recently received high attention in delivery
therapeutics using direct nose-to-brain drug delivery as it was reported
in several articles (Dalpiaz et al., 2014; Montenegro et al., 2011;
Pardeshi et al., 2013; Patel et al., 2011)
5.1.5. Co-administration with vasoconstrictors for improved delivery
The olfactory region receives its blood supply from the small
branches off the ophthalmic artery, while the respiratory region re-
ceives its blood supply from a large arterial branch from the maxillary
artery. Therefore, the respiratory region is highly innervated with blood
vessels, making it an ideal target for systemic drug absorption (Dhuria
et al., 2010). The olfactory region is often a target area for nose-to-brain
delivery, since this has fewer blood vessels contributing to plasma
concentrations, while providing access to the olfactory nerve pathways.
Dhuria et al. (2010) studied the effect phenylephrine, a vasoconstrictor
drug used for nasal decongestion, to increase the brain to plasma AUC
ratio. They tested brain concentrations after nasal administration of
neuropeptides, hypocretin-1 or dipeptide L-Tyr-D Arg. The use of the
vasoconstrictor significantly decreased the amount of drug absorbed
into the systemic circulation, it also significantly increased the amount
delivered to the olfactory bulb.
5.1.6. Permeability enhancers
The nasal epithelium can be a rate-limiting barrier for transport of
drugs directly to the brain. In targeting drug delivery to the system
circulation, many agents have been used to increase the permeation of
drugs across the epithelium (Arora et al., 2002; Behl et al., 1998; Drejer
et al., 1992; Gordon et al., 1985; Karasulu et al., 2008; Warnken et al.,
2016). Agents used to increase the permeability across a membrane are
referred to as permeation enhancers. Permeation enhancers have also
been used to overcome this barrier for targeting delivery to the CNS.
Since the nasal epithelial layer is comprised of tight junctions, per-
meation enhancers which open tight junctions may be useful in im-
proving drug delivery to the brain. Some studies have used borneol (Lu
et al., 2012), chitosan and cyclodextrins (Khan et al., 2009; Wang et al.,
2006b) to help improve direct nose-to-brain drug transport.
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5.2. Devices to help nasal delivery
The deposition from various nasal devices is typically measured as
the amount or percent deposited in defined segments of the nasal
cavity. One of the oldest nasal delivery systems is nasal drops (Kublik
and Vidgren, 1998). When administered correctly, nasal drops may
spread over a larger area than nasal sprays, but are often cleared faster
than nasal sprays as well (Hardy et al., 1985). Charlton and coworkers
reported that nasal drops possess higher deposition in the olfactory
region compared to nasal sprays if administered to the patient in a
supine position, and when formulated with mucoadhesive agents it is
able to reduce the time in which the formulation is cleared from the
area. The longest mean residence time in the olfactory region achieved
in the study was about 14min, compared to 1.3min for control solution
without any mucoadhesive agents (Charlton et al., 2007). An important
limitation of nasal drops, and nasal sprays for that matter, is that their
efficacy can be affected by patient administration technique. Nasal
drops require complex maneuvers by patients to achieve correct head
positioning for proper administration (Kublik and Vidgren, 1998).
In order to overcome the disadvantages associated with conven-
tional nasal delivery systems with regards to targeting the olfactory
region, novel delivery devices have been developed. Some studies fo-
cused on nose to brain delivery in humans utilized the Vianase™ a de-
livery system designed e.g. to delivery insulin intranasally (Craft et al.,
2012). Vianase™ is an electronic atomizer device developed by Kurve
Technology® which consists of a nebulizer attached to a vortex
chamber. Nebulized medication particles move in a vortex in the vortex
chamber and continue to exhibit this flow when leaving the device
(Giroux, 2007). This promotes deposition to the olfactory region to
maximize transport to the brain (Craft et al., 2012). Another device is
Opt-Powder by Optinose® is a bi-directional delivery device which uses
the patient's own exhalation force to emit the dose from the device
(Djupesland and Skretting, 2012). Dr Djupesland studied that access to
the olfactory region from behind (from the pharynx) and by using a
bidirectional flow, the patient blows himself into one nostril, and since
he blows himself he closes the soft palate and the airflow will turn
around and flow back to the anterior of the other nostril. This will allow
access to the olfactory region. Impel Neuropharma has developed a
device to delivery either powder or liquids through an insufflation
method similarly to that used by Optinose®, however, instead of using
the patient's own exhalation force the device uses pressurized gas to
emit the dose (Warnken et al., 2016). SipNose has developed a drinking
actuated nasal device which similarly, enables delivery of small particle
aerosols without deposition in the lower airways (Shahaf and Hadash,
2016).
For testing the delivery of nasally administered drugs different
imaging techniques are used. Gamma camera image information
(logarithmic “hot iron” intensity scale) from the nasal cavity can be
superimposed on the corresponding sagittal MRI section. The images
should be taken from the same subject and present deposition 2min
after delivery using e.g. (a) a traditional liquid spray, (b) the breath-
powered Bi-Directional™ powder device, and (c) the breath-powered Bi-
Directional™ liquid spray device (Djupesland, 2013; Djupesland and
Skretting, 2012).
5.3. Transporter interactions
CNS diseases remain difficult to treat due to poor brain penetration
of therapeutic agents. The primary limitation of uptake of these agents
is the blood-brain barrier (BBB). The BBB consists of polarized en-
dothelial cells connected by tight junctions that limit paracellular per-
meability (Graff and Pollack, 2004). Various methods have been eval-
uated to improve BBB penetration and thereby increase brain uptake.
These methods have included increasing substrate lipophilicity (to in-
crease passive permeability), increasing carrier mediated transport
across the BBB by conjugation with a substrate of an endogenous
uptake transporter (Polt et al., 1994), and decreasing efflux through
transport inhibition or chemical modification of the substrate. In ad-
dition, nasal delivery has been explored as a means to deliver substrates
to the CNS (Graff and Pollack, 2005). Previous work has shown that
efflux transporters attenuate brain uptake of substrates after nasal ad-
ministration, and that this attenuation can be overcome by nasal ad-
ministration of appropriate transporter inhibitors (Graff et al., 2005;
Graff and Pollack, 2003). These observations seem to suggest that up-
take and efflux transport systems are operative at this site.
Targeted nano-drug delivery systems conjugated with specific li-
gands to target selective cell-surface receptors or transporters could
enhance the efficacy of drug delivery and therapy. Transporters are
expressed differentially on the cell-surface of different cell types, and
also specific transporters are expressed at higher than normal levels in
selective cell types under pathological conditions (Kou et al., 2018).
Targeted nano-drug delivery systems conjugated with specific ligands
could enhance the efficacy of drug delivery. Most transporters have a
site-specific expression, which provide ideal targets for drug delivery to
increase uptake at specific site or enhance permeation across biological
barriers such as the blood–brain barrier. Transporters usually have
broad substrate selectivity whereas the ligands for the receptors are
much more specific. These differences could actually offer certain ad-
vantages in selecting cell-surface transporters for nano-drug delivery
systems as it provides multiple choices in terms of ligands for mod-
ification of the surface of the nanoparticles to target the transporters
(Kou et al., 2017). Lack of immunogenicity of such ligands is also an
advantage.
Hada et al. (2017) demonstrated that imatinib, a P-glycoprotein (P-
gp) substrate is rapidly transported into the brain via the olfactory re-
gion after nasal administration. If imatinib is given IV then it rapidly
penetrates and removed from the brain. Following intravenous ad-
ministration, the brain/plasma ratio for imatinib was calculated to be
2% and remained at this ratio for 30min. The brain/plasma ratio fol-
lowing intranasal administration, however, was found to be 5.3% and
remained at this ratio for up to 90min. If imatinib was administered
intranasally together with either pantoprazole or elacridar, compounds
known to be P-gp and breast cancer resistance protein (BCRP) sub-
strates, the amount of imatinib was significantly increased in the brain,
(especially following concurrent administration of elacridar), showing
that it is possible to increase both the amount of imatinib inside the
brain as well as the duration staying of the drug inside the brain, pre-
venting it from being removed by the P-gp, following intranasal ad-
ministration. The increased brain concentration of imatinib (0.33 μg/g
tissue) achieved by intranasal administration, compared with an IV
injection, is likely to provide a model for developing a wide range of
CNS active molecules that were previously removed from consideration
as drug candidates due to their lack of CNS access.
6. Advantages and limitations of intranasal drug administration
BBB is the delicate network of blood vessels having tightly packed
endothelial cells which separates the brain from circulatory system. It
protects brain from entry of unwanted or harmful substances such as
various chemicals and toxins. Hydrophilic substances, charged mole-
cules, proteins and peptides are unable to cross this barrier, whereas
lipophilic drugs such as antidepressants, anxiolytics and many hor-
mones can more easily cross the endothelial cells (Bates, 2014; Khan
et al., 2017). Patients suffering from neurological disorders required
chronic dosing, leading to side effects in non- targeted organs. It is
considered that majority of drugs which are useful to treat the neuro-
logical disorders have lost their potential due to the BBB, resulting in
limited treatment options for the patients suffering from neurodegen-
erative diseases and brain cancer (Pardridge, 2005). The non-invasive
transport of drugs to brain is highly needed for neurological disorders
and brain tumors requiring chronic therapy. Olfactory and trigeminal
pathways are reliable alternative to achieve desire therapeutic effects at
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lower doses for treating chronic diseases while minimizing the side
effects. Transmucosal delivery of drugs through olfactory or trigeminal
pathways to brain bypassing the BBB is referred as the direct IN drug
transportation to brain. This is the only route through which brain is in
connection with the outside environment (Mistry et al., 2009).
Besides the advantages, the limitations of nose-to-brain delivery
have also been identified, and include a relatively small volume for
administration of the drugs, limited surface area of the olfactory epi-
thelium, short retention time for drug absorption and influence a nasal
secretion on drug delivery (Wu et al., 2008).
The main points of advantages and shortcomings of intranasal drug
delivery are summarized in Table 5.
7. Discussion and conclusion
There is a long list of drugs that have been developed for various
CNS disorders, that have been discarded because they did not pass
through the blood-brain barrier. Majority of research and development
projects have, therefore, been focusing on the development of new
molecules that are able to pass through BBB. Little focus has been on the
delivery systems and searching for routes to bypass the BBB. Recently
another factor has made this field, “drug delivery to the brain” more
complex, is the discovery of efflux mechanisms in the brain and other
membranes. Studies have shown that there are many molecules that
may have access into the brain, such as imatinib, but are removed from
the brain almost immediately. This leaves us with the question: How do
we bypass the blood-brain barrier and keep the drug inside brain? In
this review the focus is on one delivery route, that has been shown to
bypass the BBB and allows a direct access to the brain. The so-called
nose-to-brain pathway. It requires that the molecules get absorbed by
the nerves inside the nasal cavity, either the olfactory nerves or even
the trigeminal nerve.
There is a growing demand for new and more potent CNS drugs and
with increasing knowledge in the pathways and functions inside the
brain, the need for new therapeutics increases as well. One field where
there has been an increased demand is within neurodegenerative dis-
orders. Here, the pathogenesis of these diseases are not enough clar-
ified, but also that the drug molecules are not able to reach the target
tissue in the brain at an appropriate concentration level. By using in-
tranasal administration a proper drug concentration in the brain par-
enchyma may be reached. This show the importance of finding routes
that are able to bypass the blood-brain barrier. Numerous research
groups have been looking at the absorption of the drugs from the nasal
cavity and how they are transported via intercellular (extracellular) or
transcellular by endocytosis into the olfactory sensory neurons. After
the neuronal uptake, the molecules move away along the axons to the
synapse where they are exocytosed onto the olfactory bulb (Fig. 3) and
transported further into the brain via various neuronal pathways.
There is also another possibility, since the olfactory mucosa is the
only site where the central nervous system is in a direct contact with a
mucosal surface. Here, a compound may be absorbed to the lamina
propria trough the paracellular space of the olfactory mucosa. From the
lamina propria, is transported through the perineural space to the
subarachnoid space from where it can reach directly the brain tissue
(Fig. 2).
Besides the direct nose-to-brain pathways, there are other routes for
the drugs to penetrate the brain. Namely from the respiratory route
they can be transported partially to the circulation and reach the brain
by the “nose-to-blood-to-brain” pathway.
Today, one of the factors that need to be respected is the role of drug
transporters or efflux transporters as described in Chapter 5.3. New
drugs must be studied with respect to their ability to be removed by
these efflux transporters or if it possible to use specific inhibitors that
may improve the therapeutic efficacy and pharmacokinetic profile in-
side the brain of CNS targeted drugs following intranasal or in-
traolfactory administration. There are also possibilities to use phar-
maceutical and technological approaches to improve the CNS access of
the therapeutics, such asformulation factors, additives, nanoformula-
tions, co-administration with vasoconstrictors, lipophilicity and per-
meability enhancement techniques etc. (see Chapter 5.1).
Taken together, drug research and development in the field of in-
tranasal or intraolfactory administration to the brain is a rapidly
growing area. Several potential drugs have been described that require
nose-to-brain transport since they do not pass the blood-brain barrier
such as oxytocin, IGF-1, insulin, glutathione, and many more. In order
to reach the CNS, all these compounds will benefit from intranasal
application, compared with the classical delivery routes. As our un-
derstanding of the brain, the pathways inside the brain and the pa-
thophysiology of CNS diseases increases, there will be more demands
for new therapeutic targets in the brain, where more specific delivery
systems will be required. The olfactory route, trigeminal route (and
vomeronasal route) may provide direct access to certain regions of the
brain, that will otherwise not be reachable. There is still need for op-
timization of this route(s) as well as full understanding of dosing and
safety following nasal drug administration focusing on reaching the
neurons for a direct CNS targeted therapy.
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Advantages and limitations of intranasal drug administration. Modified from Lochhead and Thorne (2012).
Advantages Limitations
Non-invasive
Low risks of infections
Easy self-administration
Relatively large absorption area (160 cm2 in humans; 13.4 cm2 in rats)
Large olfactory epithelium area (especially in rodents) (12.5 cm2 in humans;
6.75 cm2 in rats)
Rapid absorption
Nasal submucosa is abundant in vascular and limphatic vessels
No hepatic first pass metabolism of the drugs
Direct drug delivery to the brain bypassing the blood-brain barrier
Limited for potent drugs
Small volumes (25–200 μL in humans)
Active mucociliary clearance
Short retention time
Enzymatic degradation by nasal cytochrome P450/peptidases/proteases (pseudo first
pass effect)
Low permeability for hydrophilic drugs
Absorption enhancers needed
Low nasal epithelial pH
Interindividual variability
Low CNS delivery for proteins
Nasal secretion has an influence on the absorption
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